Abstract: The present invention provides a compound of Formula I wherein R1, R2, R3, R4, R5, R6, R7, and subscripts X and n are as described herein and pharmaceutical compositions comprising one or more said compounds, and methods for using said compounds for the treatment, inhibition, or amelioration of one or more disease states that could benefit from inhibition of a coronavirus, including SARS-CoV, MERS-CoV and SARS-CoV-2. The compounds of this invention could further be used in combination with other therapeutically effective agents, including but not limited to, other drugs useful for the treatment of coronavirus infection. The invention furthermore relates to processes for preparing compounds of Formula I, and pharmaceutical compositions which comprise compounds of Formula I and pharmaceutically acceptable salts thereof.

Abstract: An algorithm for dynamic provisioning of fail-over support in Generalized Multi-Protocol Label Switching (“GMPLS”) enabled networks is disclosed. A Fault-Tolerant Routing and Wavelength Assignment (“FT-RWA”) scheme uses a pseudo-dynamic mechanism to provide such fail-over support for the GMPLS networks. The FT-RWA scheme is capable of recovering from channel and link failures within the GMPLS network. When a channel failure occurs, some wavelength channels on the link fail. As a result, traffic on the affected light paths are switched to any unused and reserved wavelengths on the same link. If no wavelengths are available, the failure is perceived as a link failure. When a link failure occurs, all or part of the traffic is redirected to a neighboring node, designated as a “redirector”. The redirector node calculates alternate routes to the destination of that link and creates a light path on a suitable route when a failure occurs.